Abstract

Liver fibrosis results from chronic liver injury in conjunction with the accumulation of extracellular matrix proteins. The present study was performed to estimate the effect of bicyclol on bovine serum albumin (BSA)-induced immunological liver fibrosis in rats. Bicyclol (1) (100, 200, and 300 mg/kg) was given to rats by oral administration once a day for 5 weeks from the fourth week of intravenous injection of BSA. Blood and liver tissues were collected for the measurement of hydroxyproline (Hyp), procollagen type III (PIIIP), hyaluronic acid (HA), and transforming growth factor β-1 (TGF-β1) levels and liver pathological changes. The mRNA and protein expressions of hepatic TGF-β1, interleukin-1 (IL-1), IL-10, MMP-2, TIMP-1, phosphorylated p38 (Pp38), and Smad2/3 were detected by reverse transcription polymerase chain reaction and Western blot. As a result, bicyclol significantly protected against BSA-induced liver fibrosis as evidenced by the reduction of elevated serum HA, PIIIP, and hepatic Hyp in rats, while liver pathological changes were also alleviated. The overexpressions of hepatic TGF-β1, IL-1β, IL-10, MMP-2, and TIMP-1 were suppressed by bicyclol in BSA-treated rats. The phosphorylations of Pp38 and Smad2/3 were also inhibited after bicyclol treatment. The hepatoprotection of bicyclol was mainly due to the modulation on the expression of inflammatory/anti-inflammatory cytokines, downregulation of hepatic TGF-β1, and inhibition of hepatic collagen synthesis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call